When Will Retatrutide Be Available?
Retatrutide is not available outside of clinical trials. It has not been approved by the FDA or any regulatory agency. Based on Eli Lilly's confirmed timeline and the status of the TRIUMPH Phase 3 program, the most likely scenario is FDA approval in late 2027 with commercial availability beginning in Q4 2027 or early 2028.
On February 2, 2026, during its Q4 2025 earnings call, Eli Lilly confirmed it remains "on track" to submit the NDA (New Drug Application) for retatrutide later in 2026. The company has also begun "at-risk" manufacturing at facilities in Concord, NC and Limerick, Ireland.
Timeline at a Glance
| Milestone | Expected Date | Status |
|---|---|---|
| TRIUMPH-4 results | December 2025 | Completed — 28.7% weight loss at 12 mg |
| TRIUMPH-3 results (cardiovascular) | February–March 2026 | Imminent |
| TRIUMPH-1 results (core pivotal) | ~May 2026 | Active |
| TRIUMPH-2 results (replication) | ~Mid 2026 | Active |
| NDA submission to FDA | Q4 2026 | On track (per Lilly) |
| FDA accepts filing | Q1 2027 | Projected |
| FDA approval decision | Q3–Q4 2027 | Projected |
| Commercial launch | Q4 2027 – Q1 2028 | Projected |
The TRIUMPH Phase 3 Program
Eli Lilly's TRIUMPH program consists of 8 Phase 3 trials enrolling over 5,800 participants globally. Two positive pivotal trials (TRIUMPH-1 and TRIUMPH-2) are required for FDA submission.
| Trial | Focus | Status | Expected Completion |
|---|---|---|---|
| TRIUMPH-1 | Obesity (core pivotal, ~2,000 participants, 80 weeks) | Active | ~May 2026 |
| TRIUMPH-2 | Obesity (replication trial) | Active | ~Mid 2026 |
| TRIUMPH-3 | Cardiovascular disease | Active | ~Feb–Mar 2026 |
| TRIUMPH-4 | Knee osteoarthritis | Completed (Dec 2025) | Done |
| TRIUMPH-5 | Head-to-head vs tirzepatide | Enrolling | ~April 2027 |
| TRIUMPH-6 | Obstructive sleep apnea | Active | ~Mid 2026 |
| TRIUMPH-7 | MASH/liver disease | Active | ~2026 |
| TRIUMPH-8 | Weight maintenance | Active | ~July 2027 |
Why TRIUMPH-1 Is the Most Important
TRIUMPH-1 is the pivotal registration trial with approximately 2,000 participants and an 80-week treatment duration — longer than TRIUMPH-4's 68 weeks. If efficacy holds at the same rate, it could show >30% average weight loss, which would be unprecedented for any obesity drug. This is the trial that will carry the NDA filing.
TRIUMPH-3: The Cardiovascular Wild Card
TRIUMPH-3 (cardiovascular outcomes) is the next readout expected imminently. If it demonstrates significant MACE (major adverse cardiovascular events) reduction, it could:
- Unlock priority review from the FDA (6-month review instead of 10)
- Enable a broader label ("obesity with cardiovascular risk")
- Accelerate the timeline by several months
FDA Review Process
Standard Review (Most Likely): 10 Months
Because three GLP-1 obesity medications are already FDA-approved (Wegovy, Zepbound, Saxenda), retatrutide will likely receive a standard 10-month review rather than priority review. The FDA's National Priority Voucher program (used for orforglipron) is unlikely to apply to retatrutide.
Potential Delays
- Dysesthesia advisory committee: The dysesthesia side effect (20.9% at 12 mg) could prompt an FDA advisory committee hearing, adding 1-2 months
- Manufacturing inspections: FDA facility inspections at Lilly's production sites could flag issues
- Complete Response Letter: The FDA could request additional data before granting approval
Three Scenarios
| Scenario | NDA Filing | FDA Decision | Launch |
|---|---|---|---|
| Optimistic (priority review) | Q4 2026 | Mid 2027 | Late 2027 |
| Base case (standard review) | Q4 2026 | Q3–Q4 2027 | Q4 2027 – Q1 2028 |
| Conservative (delays) | Q1 2027 | Late 2027 – Q1 2028 | Mid 2028 |
How to Access Retatrutide Today
The only legal way to receive retatrutide is through Eli Lilly's clinical trials:
- ClinicalTrials.gov — Search all registered retatrutide trials
- Lilly Trial Guide — Lilly's trial finder with eligibility screening
Typical Eligibility Criteria
- BMI ≥ 30 kg/m², or BMI ≥ 27 with at least one weight-related comorbidity
- Age 18+
- No GLP-1 receptor agonist use in the prior 90 days
- No history of pancreatitis, bariatric surgery, or medullary thyroid carcinoma
See Retatrutide Clinical Trials for detailed information about the TRIUMPH program and Cost & How to Get It for other access options.
Grey Market Is Not a Safe Alternative
Grey market retatrutide sold online by research chemical vendors is unregulated, untested, and not legal for human consumption. Studies show 30% of tested research peptides contained incorrect amino acid sequences and 65% exceeded endotoxin safety thresholds. See Grey Market Retatrutide: Risks and Dangers for the full safety data.
What Happens After Approval
Even after FDA approval, broad availability takes time:
| Phase | Timeline Post-Approval | What Happens |
|---|---|---|
| Controlled launch | Month 1 | Available at specialty obesity centers |
| Gradual expansion | Months 2–3 | Broader distribution to pharmacies |
| Broad availability | Months 4–6 | Widely available if manufacturing is on track |
| Insurance coverage | Months 3–12 | Commercial insurance 3–6 months; Medicare may not cover obesity drugs |
Expected Pricing
Based on Lilly's current pricing for Zepbound (~$1,060/month) and retatrutide's superior efficacy profile, analysts project retatrutide will be priced at approximately $1,200–$1,500 per month. Final pricing will be announced closer to launch.
International Availability
| Region | Status | Estimated Timeline |
|---|---|---|
| United States (FDA) | TRIUMPH Phase 3 active, NDA expected Q4 2026 | Q3–Q4 2027 |
| European Union (EMA) | Lilly opened scientific advice with CHMP in late 2024 | ~2027–2028 |
| United Kingdom (MHRA) | 150-day accelerated pathway available | Shortly after US approval |
| Canada | Parallel review programs available | Submission expected after US NDA |
| Australia (TGA) | Project Orbis-style collaboration possible | 2028+ |
| Other markets | Dependent on local regulatory processes | 2028+ |
Frequently Asked Questions
Is retatrutide available now?
No. Retatrutide is only available through clinical trials. It has not been approved by the FDA or any other regulatory agency.
When will retatrutide be FDA approved?
Based on Eli Lilly's confirmed timeline, the most likely approval date is Q3–Q4 2027. The NDA is expected to be submitted in Q4 2026, followed by a standard 10-month FDA review.
Can my doctor prescribe retatrutide?
Not yet. Once approved, retatrutide will be available by prescription. Until then, the only option is enrollment in a clinical trial.
Will insurance cover retatrutide?
Too early to know. Insurance coverage typically takes 3-12 months after FDA approval. Commercial insurance tends to be faster than Medicare. Lilly will likely offer a savings program similar to the Zepbound Savings Card.
What should I do while waiting?
Talk to your doctor about currently approved options: semaglutide (Wegovy) or tirzepatide (Zepbound) for obesity, or check eligibility for retatrutide clinical trials at ClinicalTrials.gov.
Sources
- Eli Lilly. (2026). Q4 2025 Earnings Call, February 2, 2026. Investor Relations.
- Eli Lilly. (2025). TRIUMPH-4 results. Press release.
- ClinicalTrials.gov. TRIUMPH trials: NCT05931367, NCT05934019, NCT05913128.
- NextGen GLP-1. (2026). Retatrutide FDA Approval Status: February 2026 Update. Link.
Medical Disclaimer
The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the FDA.
Do not use this information to make decisions about your health without consulting a qualified healthcare provider. If you are considering weight loss medication, talk to your doctor about currently approved options or clinical trial enrollment.
This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.
Sources
- Find retatrutide trials
ClinicalTrials.gov
- Lilly investor news
Eli Lilly
Related reading
Retatrutide FDA Approval Timeline
Confirmed and projected milestones on retatrutide's path to FDA approval.
Retatrutide Clinical Trials & Results
Living tracker of all retatrutide trials — Phase 1 through the TRIUMPH Phase 3 program.
Retatrutide Cost & How to Get It
What retatrutide might cost, how to access it through clinical trials, and why gray market peptides are dangerous.